Downloads: 47 | Views: 129
Doctoral Thesis | Medical Science | Albania | Volume 10 Issue 2, February 2021
5 Alpha - Reductase and Metabolic Syndrome in PCOS Patients
Abstract: Objectives: Polycystic ovary syndrome is one of the most common endocrine pathologies in fertile women. PCOS is an endocrine disorder characterized by a disorder of the reproductive and metabolic systems that include hyperandrogenism, ovarian dysfunction and morphological changes in the ovaries (presence of cysts) as well as other clinical and biochemical symptoms such as hirsutism, hyperinsulinemie, etc. alpha reductase deficiency is considered one of the causes of PCOS and total testosterone/dihydrotestosterone ratio (TT/DHT) it is used in the evaluation of its activity. Methods: In 70 cases diagnosed as PCOS, based on Rotterdam criteria we measured the serum levels of luteinizing hormone (LH), follicle stimulating hormone (FSH), total testosterone (TT) and DHT. TT/DHT ratio was calculated in order to reflect 5alpha-reductase activity. In all participants, anthropometric data, lipids, HOMA-IR were also assessed. RESULTS: In cases of PCOS patients we measured the level of TT (0.87±0.79) (ng/ml), DHT (29.9±11.8) (ng/dl), FSH (5.7±2.06) (UI/L), LH ( 12.7±10.2) (UI/L). We calculate LH/FSH ratio ( 2.3±1.2) and TT/DHT ratio (3.1±1.7). PCOS patients showed significantly higher levels of TT than control group. The TT/DHT ratio was significantly higher in PCOS patients (P <.005). No difference was found for total DHT levels. The studied groups were not different in terms of age, BMI and HOMA-IR. In the patients group, mean TT levels were signifcantly higher as compared to controls. In the patients group, mean TT/DHT ratio was significantly higher compared to controls The association between TT/DHT ratio and unfavorable metabolic parameters was also seen in controls. Conclusion: Total testosterone/dihydrotestosterone ratio correlates with a worse metabolic profil not only in PCOS patients, but also in healthy women.
Keywords: testosterone, dihydrotestosterone, polycystic ovary syndrome, hyperandrogenism
Edition: Volume 10 Issue 2, February 2021,
Pages: 394 - 398